RxDoctor Payments Data

Uzoma Gbulie

Plastic and Reconstructive Surgery · Mansfield, TXNPI 1851509145

Payments from drug & device makers

What this record shows

This record is dominated by education: $6,208 of the $9,521 with a category attached, or 65.2%. Acell, Inc. accounts for 65.2% of it on its own, with 13 other manufacturers making up the rest. Reporting peaked in 2019 at $6,842 and has fallen 89.8% since, to $700 in 2025.

$9,521in general payments, 2019–2025

Across 46 payments — averaging $206.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Acell, Inc.$6K
  • Musculoskeletal Transplant Foundation Inc.$865
  • Medical Device Business Services, Inc.$515
  • AbbVie$366
  • Acera Surgical, Inc.$343
  • Exsomed Corporation$228
  • plus $998 from 8 others

What the payments were for

  • Travel & lodging$91110%
  • Food & beverage$2,40225%
  • Education$6,20865%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,521 in reported general payments places this provider in the 80th percentile of 378 plastic and reconstructive surgery providers in Texas.

See all plastic and reconstructive surgery providers in Texas →

Medicare billing

Part B allowed, 2024
$34,945
Medicare patients
50
Services billed
156

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Ondansetron Hcl39$272
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen21$267
Cephalexin29$175
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen17$142

Paid to pharmacies, not to this prescriber.

Other plastic and reconstructive surgery in Mansfield

See the full list for Texas →

Where these figures come from

Is this you, or does something look wrong? →